Based on the data provided, there is not enough information to determine a clear trend for BAXALTA UK INVESTMENTS LTD. The company's average time to pay has remained consistent over the past two periods. However, there was a significant increase in the percentage of invoices paid later than 60 days in the second period compared to the first period.
There is some volatility in the data for BAXALTA UK INVESTMENTS LTD. The company's percentage of invoices paid within 30 days and between 31 and 60 days has fluctuated slightly over the past two periods, while the percentage of invoices paid later than 60 days has seen a larger increase in the second period.
From the available data, it appears that BAXALTA UK INVESTMENTS LTD. has not made significant changes in their payment practices over the past two periods. The company's average time to pay and percentage of invoices paid within 30 days have remained consistent, while there has been a slight increase in the percentage of invoices paid between 31 and 60 days. However, there was a significant increase in the percentage of invoices paid later than 60 days in the second period compared to the first period.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2018 - 31 Dec 2018 | 28 Jan 2019 | |||||
| 01 Jan 2018 - 30 Jun 2018 | 30 Jul 2018 |
BAXALTA UK INVESTMENTS LTD. is a biotechnology company that focuses on the development and production of innovative treatments for rare diseases. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact, such as investing in renewable energy sources and minimizing waste.
Their products and services include treatments for rare blood disorders, immune deficiencies, and other genetic diseases. The company also offers educational resources and support for patients and healthcare professionals.
The key people at BAXALTA UK INVESTMENTS LTD. include the CEO, Mr. John Orloff, who has over 25 years of experience in the biotechnology industry, and the Chief Operating Officer, Ms. Karen Smith, who has expertise in global supply chain management.
For any inquiries, the company can be contacted at their registered office address: BAXALTA UK INVESTMENTS LTD., 1 Basinghall Avenue, London, EC2V 5DD, United Kingdom. Their website, www.baxalta.co.uk, provides detailed information about their products, services, and sustainability efforts. BAXALTA UK INVESTMENTS LTD. is dedicated to making a positive impact in the healthcare industry while prioritizing sustainability.